BIODEGRADABLE STENTS MARKET ANALYSIS

Biodegradable Stents MarketSize and Trends

The global biodegradable stents size is estimated to be at US$ 388.9 Mn in 2023 and is expected to reach US$ 634.7 Mn by 2030, growing at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030.

Global Biodegradable Stents Market Trends:

• Introduction of newer materials: The introduction of newer materials is having a significant impact on the global biodegradable stents market. Biodegradable stents made from various polymeric materials are rapidly replacing conventional bare-metal and drug-eluting metallic stents due to distinct advantages they provide. Traditionally, stents were made from non-degradable metals like stainless steel and alloys. However, with advancement in material science and biotechnology, bioresorbable polymers are now being used extensively to manufacture stents that dissolve and disappear from the body over time. For instance, in April 23, 2023, Shanghai MicroPort Medical (Group) Co., Ltd., a medical device manufacturer announced the online publication in the EuroIntervention journal of the design of the Target-First study. This European study aims to determine whether short dual antiplatelet therapy (DAPT) is non-inferior to standard DAPT for patients with acute myocardial infarction (AMI) who have underwent complete revascularization with Firehawk, an abluminal in-groove biodegradable polymer rapamycin eluting stent.
• Innovation of custom-made designs: The innovation of custom-made designs is having a significant impact on the global biodegradable stents market. With the development of advanced 3D printing and computer modeling techniques, doctors are now able to create fully customized stents tailored specifically for each patient's unique anatomy. This shift towards personalization is increasing patient outcomes and satisfaction.
• Rising clinical trials: The rising trend of clinical trials for biodegradable stents is positively influencing the global biodegradable stents market. Clinical trials play a very important role in evaluating the safety and efficacy of newly developed biodegradable stents before they are approved for commercial use in patients. For instance, in September 2020, Abbott, a medical device company, announced the start of the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company's new Esprit BTK Everolimus Eluting Resorbable Scaffold System. This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully bioresorbable stent to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).